Renally clearable ytterbium nanoparticle contrast agents for spectral photon counting computed tomography

项目摘要 传统的CT成像在现代医学中应用非常广泛，2010年每年进行8000万次扫描。 美国. CT具有重要的心血管应用，如钙评分和冠状动脉 动脉造影一种新的CT形式正在出现，它被称为光谱光子计数CT（SPCCT）。这 一种类型的CT使用光子计数探测器，这与常规CT中使用的能量积分探测器相反。 CT. SPCCT承诺比传统CT有所改进，例如更低的辐射剂量，更高的空间分辨率， 分辨率和改进的区分材料的能力。目前使用的碘基造影剂 CT成像存在清除速度过快、靶向性差、过敏反应等不足 和肾损伤的可能性，并且特别是对于SPCCT不是理想的，因为难以对碘成像 具体来说因此，需要开发设计用于SPCCT的新的造影剂，其可以提供 更准确和更强的心血管疾病诊断。我们发现镱是最 SPCCT造影剂生成的有效元素。我们将开发新的，高度生物相容的镱 纳米颗粒造影剂用于SPCCT的高精度和低剂量心血管成像。

PROJECT SUMMARY Conventional CT imaging is very widely used in modern medicine, with 80 million scans performed per year in the USA. CT has important cardiovascular applications such as calcium scoring and coronary artery angiography. A new form of CT is emerging, which is known as spectral photon counting CT (SPCCT). This type of CT uses photon counting detectors as opposed to the energy integrating detectors used in conventional CT. SPCCT promises improvements over conventional CT such as lower radiation dose, higher spatial resolution and an improved ability to distinguish materials. The current iodine-based contrast agents used in CT imaging have several deficiencies such as very rapid clearance, lack of disease targeting, allergic reactions and potential for kidney damage, and are not ideal for SPCCT in particular since it is difficult to image iodine specifically. There is a need, therefore, to develop new contrast agents designed for SPCCT that can provide more accurate and enhanced diagnoses for cardiovascular disease. We have found that ytterbium is the most potent element for SPCCT contrast generation. We will develop novel, highly biocompatible ytterbium nanoparticle contrast agents for highly precise and low dose cardiovascular imaging with SPCCT.